Immatics N.V. — Form 20-F Summary
Business context and reporting period
Annual report for the fiscal year ended December 31, 2022; it is not a standalone fourth-quarter filing, and the supplied filing text does not provide separate Q4 financial results. Immatics is a clinical-stage biotechnology company developing T cell receptor-based cancer immunotherapies. Its consolidated statements are prepared under IFRS in euros. It has no approved products and no product-sales revenue.
Key financial metrics
| Metric | FY 2022 | FY 2021 |
|---|---|---|
| Collaboration revenue | €172.8 million | €34.8 million |
| Research and development expense | €106.8 million | €87.6 million |
| General and administrative expense | €36.1 million | €33.8 million |
| Operating result | €30.0 million | €(86.3) million |
| Net profit/(loss) | €37.5 million | €(93.3) million |
| Basic earnings/(loss) per share | €0.56 | €(1.48) |
| Cash flow from operating activities | €100.1 million | €(84.7) million |
Revenue increased about 397% year over year. The company reported an approximate 17% operating margin and 22% net margin, but these reflect collaboration and licensing revenue rather than commercial product sales and should not be treated as evidence of recurring profitability.
- Cash and cash equivalents were €148.5 million; other financial assets were €213.7 million. Combined cash, cash equivalents and other financial assets totaled €362.2 million at year-end, versus €145.1 million a year earlier.
- Total assets were €407.8 million and shareholders’ equity was €213.2 million. Current assets of €377.2 million exceeded current liabilities of €106.5 million.
- No conventional borrowings are reported in the supplied balance sheet. Lease liabilities were €14.6 million and warrant liabilities were €16.9 million. Contractual lease payments and other lease obligations totaled approximately €25.6 million.
- Operating cash flow benefited from collaboration cash receipts and a €45.6 million increase in accounts payable and other liabilities. Investing cash outflow of €209.8 million was primarily purchases of deposits and bonds, not solely operating investment. Financing cash inflow was €123.7 million, principally from equity issuance.
Material changes versus the prior comparable period
- FY 2022 profit followed losses in 2021 and 2020. The improvement was mainly due to increased collaboration revenue, including a €91.3 million license component for IMA401 and revenue recognized following GSK’s termination.
- BMS collaboration revenue was €126.1 million and GSK revenue was €37.1 million in 2022. The company reported no milestone or royalty payments in either year.
- R&D expense increased 22%, driven by clinical-trial expansion, higher staffing and IMA402 preclinical work. G&A expense increased 7%.
- Cash and other financial assets rose substantially following BMS collaboration receipts and equity financing, including an October 2022 offering of 10.9 million shares and sales under the ATM program.
Outlook, commentary, risks and unusual items
- Management stated that available financial resources were expected to fund projected operating requirements for at least 12 months from the report date. It expects significant R&D spending and losses as development advances; future funding needs depend on trial progress, manufacturing, regulatory requirements and collaboration terms.
- Planned milestones included an IMA203 clinical data update and cohort prioritization in the second half of 2023, continued Phase 1 development of IMA401, and an IMA402 CTA submission planned for Q2 2023 with a Phase 1/2 trial planned for the second half of 2023. The Houston GMP facility was expected to be operational in 2024. These are forward-looking plans, not guarantees.
- October 2022: GSK gave notice terminating its collaboration, effective December 26, 2022; Immatics regained the relevant TCRs. The filing says termination was unrelated to program progress. Separately, Genmab gave notice in January 2023 terminating one program.
- Pipeline decisions included plans to discontinue IMA201 after treating enrolled patients, no further Phase 1b expansion for IMA202 while development options are evaluated, and a delay to IMA204’s IND submission as resources were prioritized for IMA203 and IMA402.
- IMA203 interim monotherapy data reported a 50% confirmed objective response rate (6/12) among patients treated at target dose or above, and 80% (4/5) in the Phase 1b subset. These were small, open-label early-stage cohorts with limited follow-up; the filing cautions that interim results may change. A dose-limiting toxicity was observed in the first IMA203CD8 patient at dose level 4, prompting a more cautious dose-escalation approach.
- Principal risks include clinical efficacy and safety uncertainty, trial enrollment and HLA/target prevalence constraints, complex manufacturing and third-party dependence, evolving regulation, competition, intellectual-property challenges, and the potential need for additional capital. The company is exposed to EUR/USD movements; it estimated a 10% currency move could materially affect profit.
- The year’s unusual earnings drivers included €91.3 million of IMA401 license revenue, €33.4 million recognized in connection with GSK termination, and €10.9 million of non-cash income from a decrease in warrant fair value. FY 2022 also included €4.5 million of income tax expense. These items make reported profit less indicative of recurring operating performance.
- Trademark disputes involving IMMTAX/IMMATICS/IMTX remained ongoing; management did not expect existing legal proceedings to have a material adverse effect. A contingent payment for a third-party milestone is disclosed at inconsistent amounts of approximately €1.6 million and €1.9 million in different notes.
Most important facts for investors to verify
- Check the audited IFRS statements and collaboration disclosures to distinguish cash received from revenue recognized, especially the IMA401 license and GSK termination amounts.
- Review the full IMA203 and IMA401 clinical updates, including enrollment, response durability, adverse events, dose levels and whether interim data were later revised.
- Confirm the timing and cost of the Houston GMP facility and whether manufacturing capacity, quality and release timelines support planned trials.
- Assess the cash runway against forecast spending, deferred collaboration revenue, capital commitments and potential dilution from further equity issuance or warrants.
- Reconcile lease commitments and the inconsistent €1.6–€1.9 million contingent-payment disclosure; also consider the warrant liability’s non-cash volatility.
The financial statements received an unqualified audit opinion. Management reported effective disclosure controls and internal control over financial reporting; the auditor did not attest to internal-control effectiveness because Immatics was an emerging growth company.